106 related articles for article (PubMed ID: 31208798)
1. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors.
Giannini G; Milazzo FM; Battistuzzi G; Rosi A; Anastasi AM; Petronzelli F; Albertoni C; Tei L; Leone L; Salvini L; De Santis R
Bioorg Med Chem; 2019 Aug; 27(15):3248-3253. PubMed ID: 31208798
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
3. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
Lewis MR; Raubitschek A; Shively JE
Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
[TBL] [Abstract][Full Text] [Related]
4. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
[TBL] [Abstract][Full Text] [Related]
5. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
6. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy.
Wang W; Fliedner FP; Hansen AE; Eliasen R; Melander F; Kjaer A; Andresen TL; Jensen AI; Henriksen JR
Nanotheranostics; 2020; 4(3):142-155. PubMed ID: 32483520
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy.
Gritti G; Gianatti A; Petronzelli F; De Santis R; Pavoni C; Rossi RL; Cattaneo L; Spagnoli LG; Ferrari S; Rossi A; Barbui AM; Rambaldi A
Oncotarget; 2018 Feb; 9(11):9766-9775. PubMed ID: 29515769
[TBL] [Abstract][Full Text] [Related]
10. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
[TBL] [Abstract][Full Text] [Related]
11. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
12. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.
Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Nilsson R; Sandberg BE; Brechbiel M
Bioconjug Chem; 2002; 13(5):1079-92. PubMed ID: 12236790
[TBL] [Abstract][Full Text] [Related]
13. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.
Ait-Mohand S; Fournier P; Dumulon-Perreault V; Kiefer GE; Jurek P; Ferreira CL; Bénard F; Guérin B
Bioconjug Chem; 2011 Aug; 22(8):1729-35. PubMed ID: 21761921
[TBL] [Abstract][Full Text] [Related]
16. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.
Li L; Tsai SW; Anderson AL; Keire DA; Raubitschek AA; Shively JE
Bioconjug Chem; 2002; 13(1):110-5. PubMed ID: 11792185
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).
Wunderlich G; Schiller E; Bergmann R; Pietzsch HJ
Nucl Med Biol; 2010 Nov; 37(8):861-7. PubMed ID: 21055615
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
[TBL] [Abstract][Full Text] [Related]
20. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
